Full Report

Know the Business — Novonesis

Bottom line. Novonesis is a global near-monopoly in industrial enzymes and microbial cultures — a fermentation-based ingredient business where a tiny bottle of bugs and proteins drops into a customer's process and shifts yield, energy use, or product quality by a few percent. The company prints 36%+ adjusted EBITDA margins, grows organically 5–9% a year, and is a decisive #1 in most of its end markets. The market's tension today: a stellar operating business has been half-buried under a EUR 12B Chr. Hansen merger — goodwill is now 37% of assets, reported ROIC has collapsed from 19% to 6%, and the real debate is whether the combined entity can deliver the promised revenue synergies on top of already-booked cost savings.

1. How This Business Actually Works

Novonesis sells catalysts — literal or biological — that let customers get more output from the same inputs. The end customer (Unilever, Coca-Cola, Danone, Bunge, POET) does not buy "enzymes"; they buy 1% higher cheese yield, 30% less surfactant in laundry detergent, or extra ethanol per bushel of corn. The enzyme is 1–2% of the customer's bill of materials but protects 100% of the end product's performance. That asymmetry is the entire economic story.

Why the margins are so high. The strain library is the moat: microbes selected and engineered over 80+ years, producing enzymes no one else can match on activity-per-gram or thermal stability. Customers design their factory process around a specific enzyme; switching means re-running months of trials and re-certifying with regulators or retailers. That is the gross margin: 53.9% reported, 59.1% adjusted. R&D at ~11% of sales is essentially a permanent tax that protects those margins — stop spending and the library ages, as Novozymes learned when Chinese generic enzyme producers came for the commoditizing end of the portfolio around 2018–2020.

Incremental profit is lopsided. Once a fermentation line is built, marginal cost of another batch is close to variable raw-material and utilities. That's why the FY2025 adjusted EBITDA margin hit 37.1% and is guided to grind higher — volume leverage plus merger cost synergies (80% of run-rate already booked in year one). The constraint is capacity, not demand: capex ran 11.3% of sales in 2025 and is guided to stay elevated for planetary-health expansion.

2. The Playing Field

Novonesis sits at the top of a small, concentrated pyramid. Only three companies matter in enzymes globally — Novonesis (~48% share), IFF (post-DuPont N&B, ~20%), and a long tail of Chinese producers (Vland, Sunson, Longda, collectively ~15%). In cultures, Novonesis and Chr. Hansen were the two global players; the merger collapsed the duopoly into a monopoly with ~70% global share in dairy cultures and ~50% in probiotics.

What the peer set reveals. The flavors-and-fragrances camp (Givaudan, IFF, dsm-firmenich) looks similar on the surface — also ingredient-IP businesses — but their margins sit 15–20 points below Novonesis. Why the gap? F&F plays in consumer flavors where brand and application development compete against lower technical switching costs; customers can reformulate. Novonesis plays in process enzymes and cultures where switching requires revalidating an entire industrial process or meeting regulatory safety rules for infant formula or pharma. IFF's FY2025 numbers are the cautionary tale: the DuPont N&B deal created a business too diverse to manage, ROIC is negative, and EBITDA margin is less than half Novonesis'.

Novonesis' relative weakness: customer concentration in certain divisions (detergents: Procter & Gamble + Unilever + Henkel are ~50% of Household Care sales) and heavy dependence on emerging-market ethanol production for the Planetary Health growth engine. Kerry is the best-run mid-cap peer operationally but doesn't touch industrial enzymes. The takeaway: there is no real second source for what Novonesis sells — the closest peer (Chr. Hansen) now sits inside the company.

3. Is This Business Cyclical?

Much less cyclical than "Specialty Chemicals" suggests — more like a slow-beating consumer staple with two cyclical tails. The core business (detergents, dairy, probiotics, infant nutrition) is tied to daily consumption and was resilient through 2008, 2015, and 2020. The cyclical tails are bioenergy (ethanol demand tracks gasoline demand and crop prices) and Human Health / Dietary Supplements (sensitive to US consumer discretionary spending and retailer destocking). Working capital can absorb 1–2% of revenue in a destocking year, which you saw in the Plant agriculture division in 2024.

Read the chart this way. Margins dip but rarely collapse — worst trough was 2023 at 33.2% when the fossil-energy cost spike from Russia's invasion of Ukraine hit Danish and Spanish fermentation plants (gas-intensive), and simultaneously customers worked down inventory built during COVID. Organic growth troughed at 0% (2020) and 5% (2023). This is not cyclical like basic chemicals; this is "growth can pause, margins compress by 300bps." The cycle hit was in volume and raw-material spreads, not in pricing — management held price through both shocks.

Where you actually should worry. The business is not recession-cyclical but it is exposed to: (1) ethanol policy and crop margins in the US/Brazil — Planetary Health's Energy subarea is ~12% of group sales and double-digit growth is priced in; (2) Chinese dairy consumption, which has been declining since 2022 and hit the Food & Beverages division's Dairy subarea; (3) emerging-market FX translation — ~36% of sales are emerging markets and 2025 organic growth of 7% was reported as only 5% in EUR once currency hit.

4. The Metrics That Actually Matter

Five numbers explain this stock. The consensus ratios do not. Forget P/E — merger-accounting noise (PPA amortization, one-time inventory step-up) will distort reported earnings for the next 5–7 years. Watch these instead.

Read this scorecard. Growth is stable in a tight band. Margin is structurally expanding. ROIC ex-goodwill is the most interesting — it fell from 21% pre-merger to 10% post-merger because the dsm-firmenich feed enzyme business was bought at a premium (EUR 1.5B for ~EUR 200M of EBITDA, absorbed in 2025). Management target is to work ROIC back to mid-teens via synergy realization over 2026–2028. If they hit it, the multiple re-rates; if they don't, the stock is a dead weight that earns a 5% cash return.

What consensus watches but you should discount. Reported EPS — distorted by ~EUR 235M/yr of PPA amortization. Reported ROIC including goodwill — mechanically penalized by the merger regardless of operating performance. Gross margin — dropped from 57.7% to 47.2% in 2024 purely from PPA inventory step-up, while adjusted gross margin actually rose from 54.3% to 59.1%. These optics have already scared off some generalist funds, which is part of the setup if the thesis works.

5. What I'd Tell a Young Analyst

Watch three things, ignore most of the noise, and understand where the thesis breaks.

Watch: (1) Revenue synergy delivery. Management has promised sales synergies on top of the cost synergies mostly already banked — plausibly EUR 200M of high-margin revenue by 2028. Each quarterly call will disclose a synergy number; the cost side has been over-delivered, the revenue side is unproven because it requires actually cross-selling Novozymes enzymes to Chr. Hansen dairy customers, which sales organizations rarely execute well post-merger. (2) Household Care deceleration. FY2025 Household Care growth was a structural outlier at 13%, driven by an unusual European detergent-volume recovery. Guidance is for normalization — if it re-accelerates, there is real upside; if it goes to 3% you know the 2024 number was a pull-forward. (3) dsm-firmenich feed enzyme ramp. EUR 1.5B acquisition closed 2025 and goes inside Planetary Health. Early signal of whether the acquisition playbook works for bolt-ons, or whether Novonesis only knows how to buy other Danish biotech companies well.

Ignore: P/E, reported ROIC including goodwill, any broker model that compares Novonesis with Evonik or BASF. They are not peers. The reference frame is Givaudan on economics, Linde on capital intensity, and Nestlé on customer stickiness.

What would genuinely change the thesis. A sustained drop in organic growth below 4% for two consecutive years, because it would mean the ingredient moat is eroding — that is the only way this business becomes interesting to short. Also: a second generic enzyme breakthrough from Chinese producers hitting industrial laundry, which would force Novonesis to lean on volume and R&D output to defend share. And: any sign that management dilutes the pure-play strategy with a non-biosolutions acquisition. The focus on fermentation-and-nothing-else is half of what produces the 37% margin. If Ester Baiget or her successor starts buying chemical businesses, the multiple should compress immediately.

The Numbers

Novonesis is the world's largest industrial-biosolutions company — enzymes, probiotics and microbial cultures sold into food, feed, bioenergy, household care and human health. Since the Novozymes/Chr. Hansen combination closed on 29 January 2024 and the Feed Enzyme Alliance (DSM-Firmenich stake) buyout in 2025, the P&L has three distinct regimes: a high-margin standalone Novozymes (2020-2023, ~33% adj. EBITDA margin on ~EUR 2bn sales), a merger-reset 2024 (~EUR 3.8bn reported, goodwill ballooning to EUR 5.6bn, a one-off PPA drag), and a cleaner 2025 (EUR 4.16bn sales, 37.1% adj. EBITDA margin, 7% organic growth). The stock now trades at roughly 41x IFRS trailing EPS and 26x adjusted-ex-PPA EPS against a consensus 2026 P/E of 33x — a structural quality premium hinged on the adjusted EBITDA margin holding 37-38% while capex steps up to 12-14% of sales for the 2030 GROW plan. That margin trajectory, and whether the Agriculture/Energy/Tech unit re-accelerates from Q4's 0% organic growth, is the single lever most likely to rerate or derate this name.

All financial statement figures are in EUR (reporting currency); share price and dividends are in DKK (listing currency, Nasdaq Copenhagen). Pro-forma 2024 numbers treat Chr. Hansen as if owned from Jan 1, 2024.

Snapshot

1. Is this a well-run business that will still be around in 10 years?

Novonesis scores well on the durability questions: a 37% adjusted EBITDA margin, mid-single-digit organic growth, a 59% adjusted gross margin and NIBD/EBITDA comfortably under 2x. The catch is ROIC: including the EUR 5.6bn of goodwill from Chr. Hansen, adjusted ROIC is just 5.6%. Excluding goodwill it recovers to 10.1% — not great, not disastrous — and the 2030 strategy explicitly targets organic ROIC expansion as cost and revenue synergies annualise.

2. Revenue & earnings power — 5-year view

Only 5 years of clean IFRS history are available; Novonesis as a reporting entity was created on 29-Jan-2024. Pre-2024 figures reflect Novozymes standalone, so year-on-year comparability is limited. We show both IFRS-reported and key pro-forma markers for context.

Revenue nearly doubled in 2024 from consolidating Chr. Hansen, and 2025 is the first clean year under the combined perimeter — 7% organic growth plus merger synergies driving EBIT ex-special items to EUR 883m, a new high.

The headline is not a fall in the true margin — adjusted EBITDA margin expanded from 33.2% in 2023 to 37.1% in 2025 — but an optical drag from IFRS 3 purchase-price-allocation amortisation. Reported EBIT margin dropped from 26% to 17% in 2024 on PPA step-ups, then recovered to 21% in 2025 as synergies annualised.

Quarterly direction (last 8 quarters, IFRS)

3. Cash generation — are the earnings real?

Cash conversion is unusually clean. Operating cash flow of EUR 1,222m in 2025 was 2.1x reported net profit — driven by the non-cash PPA amortisation that suppresses reported earnings. On a 5-year trailing basis, cumulative OpCF is EUR 3.88bn vs cumulative net profit of EUR 2.22bn, a CFO/NI ratio of 175%. FCF before acquisitions rose 16% y/y to EUR 770m despite capex stepping up to 11.3% of sales from 9.4%.

4. Capital allocation — last 5 years

Capital allocation is disciplined but has pivoted hard to growth: capex is rising toward 12-14% of sales for the 2030 GROW plan (production-capacity expansion), 2025 absorbed EUR 1.52bn in net acquisitions (buying out DSM-Firmenich's Feed Enzyme Alliance stake), dividends of EUR 403m were paid (DKK 6.50 per share for 2025 vs DKK 6.20 in 2024), and the group re-opened share buybacks at modest scale (EUR 100m). With NIBD/EBITDA at 1.9x vs target ~1.7x, buybacks are likely capped until leverage eases.

5. Balance sheet — goodwill, debt and the shape of the merger

The balance-sheet story is simple: goodwill of EUR 5.6bn now represents 34% of total assets — the Chr. Hansen transaction set the bar for what Novonesis must out-earn. Net debt jumped to EUR 2.73bn in 2025 on the Feed Enzyme Alliance acquisition, but NIBD/EBITDA at 1.9x remains below the 2x the market typically treats as an investment-grade ceiling, and management has guided leverage back to ~1.7x by year-end 2026. The EUR 1.7bn bond issue in March 2026 replaces the bridge facility.

6. Valuation — what the market is paying

The stock peaked at DKK 501 at end-2021, de-rated sharply through 2022 on merger-arb and macro concerns, then traded sideways through the Chr. Hansen integration. Today's DKK 382 is ~24% off the 2021 peak despite revenue roughly doubling — the rerating work is still ahead.

Depending on which earnings line you trust, Novonesis trades at 26x (adjusted ex-PPA) to 41x (IFRS) trailing. The forward 2026 consensus P/E of 33x compares to MarketScreener's sector median (specialty chemicals) EV/EBITDA of ~7.3x; Novonesis trades at ~20x trailing EV/EBITDA — a structural premium consistent with its 37% margins, mid-single-digit organic growth, and the regulatory moat of its enzyme IP and fermentation manufacturing base.

7. Peer comparison — biosolutions / industrial chemistry

Peer multiples are approximate TTM estimates from recent sell-side and MarketScreener snapshots; used only for relative positioning.

Novonesis is the highest-margin, fastest-growing integrated biosolutions pure-play in the set. Givaudan trades richer on P/E (32x vs 26x) but has half the EBITDA-growth profile and a similar margin; IFF and DSM-Firmenich trade at lower multiples because both carry execution risk from prior mega-mergers that have yet to recover their pre-deal earnings. The ~20x EV/EBITDA Novonesis commands is the tax for being the cleanest name in a messy industry.

8. Fair value — bear / base / bull

The base case of ~DKK 455 sits on top of the 17-analyst consensus average and implies the 2026 adjusted EBITDA margin guide of 37-38% is delivered. The bull case of DKK 545 matches SEB's current target and requires merger synergies to annualise into 2027 EPS, capex ratios to start declining, and ROIC ex-goodwill to move toward the mid-teens. The bear case of DKK 320 would require organic growth to fall below 4% while capex stays elevated — not a remote scenario if the Q4 Planetary Health weakness persists.

---

Bottom line

The numbers confirm that Novonesis is a high-quality franchise: 37% adjusted EBITDA margins, 175% five-year cumulative cash conversion, single-digit organic growth with pricing, and a moat rooted in enzyme IP and fermentation manufacturing. They contradict the view that the Chr. Hansen merger has already paid for itself — adjusted ROIC including goodwill is still only 5.6%, and the EUR 5.6bn goodwill block means any lasting underperformance would invite impairment risk. What to watch in 2026: whether Agriculture, Energy & Tech recovers above the 4% organic run-rate shown in Q4; whether capex peaks below the 14% of sales upper guide; and whether management delivers the promised 37-38% adjusted EBITDA margin even with the USD headwind that is only 72% hedged.

The People Running Novonesis

Governance grade: B. The combined company has a credible CEO, a clear controlling shareholder aligned with long-term science-driven stewardship (the Novo Nordisk Foundation), and a Danish-standard board. But a dual-class structure concentrates 63% of votes in 26% of capital, CEO pay roughly doubled to DKK 50.8M in the merger year (top-5 in the C25), and the board includes several non-independent Novo Holdings nominees. Alignment is strong at the principal-shareholder level, weaker at the individual-executive level.

1. The People Running This Company

Novonesis is run by a 10-person Executive Leadership Team dominated by ex-Novozymes leaders (roughly two thirds of the ExLT), with CEO Ester Baiget as the unifying figure. Only a handful of roles actually drive investor-relevant decisions.

Ester Baiget (CEO, since Feb 2020). Spanish chemical engineer who spent 25 years at Dow, rising to Business President of Dow's Industrial Solutions unit before being recruited to run Novozymes. She has now led the company through the most consequential event in its history — the Chr. Hansen merger — and delivered pro-forma organic growth of 8% and an adjusted EBITDA margin of 36.1% in year one, at the top of the initial guided range. Awards (PwC "Danish Business Leader of the Year 2024", Forbes Sustainability Leaders) and a Vice-Chair role at The B Team signal an external profile unusual for a Danish industrial CEO. Execution risk for the investor thesis is tied tightly to her continuation through the synergy run-rate period (through 2026).

Rainer Lehmann (CFO, since Nov 2023). Joined from Sartorius, where he was CFO for six years during its transformation into a global bioprocessing leader. His installation just before the merger close — replacing long-standing Novozymes CFO Lars Green — gave Novonesis a finance chief without legacy allegiances to either merger partner. Useful for neutral integration, but still early in tenure (operating through his first full post-merger cycle).

Cees de Jong (Chair, since 2024). Former CEO of Chr. Hansen and DSM Pharma Products; currently also Vice Chair of Novo Nordisk and Chair of Oterra (the lactase/colors business divested during the merger). Deep ingredient-biotech experience. The multi-hat Novo Group chair exposure (Novonesis, Novo Nordisk, Oterra) is a real governance flag — see Section 4.

2. What They Get Paid

CEO total remuneration roughly doubled in 2024 on merger completion — from around DKK 25M in the Novozymes years to DKK 50.8M in the first Novonesis year, making Baiget the second-highest-paid C25 CEO by Finans's ranking and the fourth highest by Wikipedia's subsequent tally. On a company now roughly twice the size of pre-merger Novozymes, the step-up is defensible, but the pace and magnitude are aggressive relative to Danish norms.

Is it earned? Shareholders got 8% organic growth, 230bps of margin expansion, dividend maintained at DKK 6.20 for the year, and a EUR 100M buyback launched for 2025 — a strong first merger year. But the structure — roughly 45% long-term equity, 20–25% STI, 30% fixed + pension — puts most of the gain in share-linked comp, which benefited from the merger-completion re-rating more than from operating delivery alone. For comparison, the company targets long-run organic growth of 6–8% and EBITDA margin 37–38%. Meeting those is the bar that justifies pay at this level persisting past 2024.

3. Are They Aligned?

Ownership and control

Novonesis has two share classes: A-shares (10 votes) and B-shares (1 vote). Novo Holdings, a wholly-owned subsidiary of the Novo Nordisk Foundation, owns all A-shares plus some B-shares — 25.5% of capital but 63.35% of votes. The Foundation's articles require it to always hold at least 25.5% of capital and a majority of the votes. In practice, activist intervention or hostile takeover is impossible without Foundation assent.

Insider buying and selling

No material open-market buying or selling by executives has been disclosed in the available Danish filings (Finanstilsynet flaggings) or via Simply Wall St's insider-trading feed for the 12 months since listing. The Danish regime requires prompt disclosure of manager transactions; the absence of sustained insider activity in either direction is normal for a controlled European company but means there is no "price-signal" from management behavior either way.

Dilution and share issuance

The only large issuance in recent years was the merger-consummation capital increase in January 2024: EUR 9.07B nominal equity issued to Chr. Hansen shareholders in exchange for shares. That is a shareholder vote outcome, not a dilutive act. Ongoing LTIP grants are modest relative to the float. A EUR 100M buyback for 2025 signals that dilution is not a concern for management.

Related-party behavior

The Novo Holdings relationship is the main related-party lens. Three links to watch:

• Chair Cees de Jong also chairs Oterra (Chr. Hansen's lactase-color unit divested during the merger to an EQT-controlled vehicle) — a legitimate capability link but a latent conflict on any future dealings.
• Kasim Kutay sits on the Novonesis board as CEO of Novo Holdings and is simultaneously on the Novo Nordisk board. Capital allocation at one Novo Group company is visible to the other.
• The Feed Enzyme Alliance wind-down with dsm-firmenich (EUR 1.5B cash consideration announced Feb 2025) is an arm's-length transaction with an unrelated counterparty — not a related-party concern.

No disclosed related-party transactions of concern between Novonesis and Novo Holdings in 2024. Management compensation, advisory fees, and service contracts are disclosed in line with Danish Corporate Governance Code.

Capital allocation behavior

Policy is a 40–60% dividend payout plus opportunistic buybacks once leverage targets are met. NIBD/EBITDA was 1.4x at end 2024 — deleveraging from the merger remains the priority, constraining buyback size. The Feed Enzyme Alliance buyout at EUR 1.5B is a logical portfolio move but tests capital discipline; investors should watch the return on that capital through 2026–2027.

Skin-in-the-game score

7/10. The Foundation's perpetual 25.5%+ holding is the strongest possible "skin" a public company can have: the controlling shareholder is structurally unable to sell. Executive ownership is less impressive — CEO and CFO have moderate share positions through vested LTIP, but nothing disclosed at the level of "personal wealth concentrated in this stock." Score is dragged down from 9 to 7 by that asymmetry and by pay being weighted toward share-linked comp rather than required personal cash purchases.

4. Board Quality

Where the board is strong: Finance expertise is exceptional — an Audit Chair (Dalsgaard) who is a sitting C25 CFO, plus Brandgaard (ex-Novo Nordisk CFO) and Kaae (ex-Bestseller CFO). Scientific depth is adequate through Sommer (professor of biosustainability at DTU) and the operating experience of de Jong and Stratton. The committee structure matches Danish Corporate Governance Code.

Where it is weaker: Three of the nine directors (Kutay, Dalsgaard via Oterra, de Jong via Oterra and Novo Nordisk) have some form of Novo Group linkage. That is inherent to the ownership structure — but in practice the independent directors must carry the weight of challenging both management and the controlling shareholder. The addition of Monila Kothari on a one-year term in April 2025 was the most recent refresh.

5. The Verdict

Grade: B.

Strongest positives

• Foundation-anchored ownership provides the longest patience horizon available in public markets and has historically sustained industry-leading R&D intensity.
• CEO has delivered — 8% organic growth and 36.1% EBITDA margin in year one of the most complex merger in European specialty chemicals since Syngenta.
• Board has real financial and scientific expertise; independent majority; active refresh.
• Capital policy is conservative and disclosed (40–60% payout, deleveraging then buyback).

Real concerns

• Vote concentration. 26% of capital controls 63% of votes. Minority holders cannot force change. This is an accepted feature of Danish foundation-owned companies, but it should be priced in.
• CEO pay step-up. DKK 50.8M in 2024 is defensible given the doubling of company scale, but a repeat in 2025 without commensurate operational delivery would be a legitimate say-on-pay event.
• Chair conflicts. Cees de Jong's three Novo Group roles (Novonesis Chair, Novo Nordisk Vice Chair, Oterra Chair) are a governance thinness point; replacement with a fully independent chair would be an upgrade.
• Executive skin-in-the-game is moderate, not high. The Foundation carries the alignment burden.

The single item most likely to change the grade

• Upgrade trigger: A separation of the Chair role from other Novo Group seats + a Novonesis-specific MSOP-style "pay-for-performance" framework where LTIP vesting is tied to 3-year ROIC/organic-growth gates rather than merger-year share price inflation. This would move the grade to B+/A-.
• Downgrade trigger: Any related-party transaction with Oterra, Novo Nordisk, or a Novo Holdings portfolio company that is not obviously arm's-length; a second year of CEO pay above DKK 50M without clear operational linkage; or an acquisition that materially impairs return on invested capital. Any one would push toward B-.

The Full Story

Between 2022 and 2025 the story changed fundamentally: Novozymes went from a self-described "pure-play enzymes" company to Novonesis, a 4.2 bn EUR biosolutions platform built on the largest merger in Danish history. Management has so far delivered what it promised for the combination — cost synergies hit 100% run-rate a year early, every quarterly outlook has been met or raised until the very last one, and the single-year narrative is clean. The quieter subplots are less tidy: the 2022 vintage "double sales by 2030" promise has been retired and replaced with a more modest 6–9% CAGR GROW strategy, adjusted ROIC including goodwill has halved from the pre-merger 18% range to 5.6%, net debt has tripled since 2023 to 1.9x EBITDA after the 1.5 bn EUR Feed Enzyme Alliance buy-out, and Q4 2025 became the first quarter to undershoot consensus. Credibility is intact but no longer unconditional.

1. The Narrative Arc

The revenue line tells the arc visually: three years of mid-single-digit growth (5–9% organic) inside a 2.0 bn EUR company, then a step-change in 2024 when Chr. Hansen consolidates, then a full year of execution at 4.2 bn EUR. The pro forma view reveals the underlying business was growing 7% organically before and after the combination — management's claim that scale did not dilute growth is, so far, supported by the numbers.

2. What Management Emphasized — and Then Stopped Emphasizing

The clearest way to read this company is by what disappeared from the CEO letter between 2022 and 2025.

The heatmap makes three patterns unmistakable:

• The 2022–2023 financial framework was retired silently. The pre-merger promise — 5%+ organic CAGR, 26%+ EBIT margin, 20%+ ROIC including goodwill, and "double sales by 2030 vs. 2020" — has simply disappeared from the 2024 and 2025 reports. No walk-back, no "previous targets achieved / superseded" footnote. It was quietly replaced with 2030 GROW targets (6–9% organic, ~39% EBITDA margin, ~16% ROIC excluding goodwill), announced in August 2025. The goodwill-exclusion matters: on a like-for-like basis ROIC now runs at 5.6% including goodwill, a long way from the old 20% bar.
• "Explore — carbon capture, PET recycling, biological plastic, precision fermentation" was a signature theme of the Novozymes 2022 letter. It has faded by 2024. Saipem carbon-capture and Carbios PET recycling are name-checked less each year; the 2025 CEO letter leads on AI in R&D instead.
• The operating KPI changed. Through 2022–2023 the headline profit number was EBIT margin before special items (target 26%). Post-merger the headline is adjusted EBITDA margin (a different animal — it excludes PPA depreciation, amortization, and integration special items, and therefore strips out the cost of the deal). EBIT margin on IFRS basis went from 26% pre-merger to 13–20% post-merger; adjusted EBITDA margin held at 36–37%. The KPI shift is economically defensible but it also flatters the story.

3. Risk Evolution

What became more important: currency (H1 2025 raised the EBITDA margin guide specifically to "despite strong currency headwinds," and Q3/Q4 2025 commentary is dominated by USD drag); tariffs (first mentioned as a 2025/2026 outlook caveat, now material to planning); and leverage (NIBD/EBITDA ran at 1.0x through 2022, ended 2025 at 1.9x after the Feed Enzyme Alliance bridge loan, peaked at 2.1x intra-year).

What disappeared: "Volatility of agriculture-related business" was a top-four risk in every Novozymes report from 2022 and 2023 — it vanishes from the 2024 risk grid. This is not that the agriculture cycle got safer; it is that the combined company is more diversified (Food & Beverages + Human Health are now 45% of sales), so ethanol / BioAg volatility became less existential and was folded into "Volatility in energy and raw material prices."

What appeared: integration risk (new 2023, peaked 2024, receding in 2025 as synergies hit 100% run-rate) and, more recently, the Russia/Belarus exit narrative — first disclosed at Q4 2024 as "exit from certain countries" (sub-footnote), now recurring in every 2025 quarter because it is the reason the group's reported organic growth is running 1–2 percentage points below the "ex-exit" figure the company prefers to cite.

4. How They Handled Bad News

For a company whose story is dominated by a transformational merger, genuine misses have been rare — and that itself is meaningful evidence about both execution and narrative management.

The pattern: management does not hide misses but it does not concede them either. The 2022 food-gain shortfall was reported cleanly. The 2023 growth deceleration was reframed as the right context for the Chr. Hansen combination. The dramatic 2024 IFRS EPS and ROIC compression was de-emphasized by shifting the headline KPI and attributing the drag to PPA amortization — technically correct, but it means investors looking at the clean adjusted number are underweighting the fact that ~1 bn EUR of goodwill and intangibles now sits on the balance sheet. The Q4 2025 miss is the first event that analysts have treated as a miss rather than a bookkeeping matter, and the narrative response — tariffs, currency, timing — is so far unchallenged.

5. Guidance Track Record

Credibility score: 7/10. What this reflects: the core near-term operating promise machinery is working. Initial outlook has been met or beaten every year the team has owned the Novonesis entity, cost synergies arrived a full year early (rare in large mergers), and the integration milestones cited in FY2023 for FY2024 all landed on time. Against that, four things pull the score below 8: (1) the pre-merger 2025 targets and the "double sales by 2030" headline were quietly retired rather than reconciled; (2) Q4 2025 is the first consensus miss since the merger closed, and the 2026 guide of 5–7% sits at the low end of the just-launched 2030 GROW range; (3) the primary profit KPI changed at the convenient moment, masking a real step-down in EBIT margin and ROIC once goodwill is included; (4) the "exit from certain countries" footnote has quietly become a recurring 1–2 point organic growth headwind without a clear end date.

6. What the Story Is Now

Novonesis today is a different, bigger, and arguably better business than Novozymes was in 2022, but it is telling a simpler story than it used to, and the simplification is doing real work.

What has been de-risked. The merger itself — the single largest source of execution risk in 2022–2024 — is functionally done. Integration milestones delivered, cost synergies at 100% run-rate a year early, sales synergies contributing ~1 pp to growth, no visible cultural blow-up, and the combined portfolio is genuinely more diversified (Food & Beverages 33%, Ag/Energy/Tech 36%, Household Care 19%, Human Health 12%). Underlying organic growth is running in the 6–8% band with a 37%+ adjusted EBITDA margin — a profile that would be an excellent outcome for a specialty chemicals business of this size.

What still looks stretched. The 2030 adjusted ROIC target of ~16% is set excluding goodwill — a choice that matters, because adjusted ROIC including goodwill is 5.6% today and the new Feed Enzyme Alliance acquisition adds another 1.5 bn EUR of goodwill-heavy assets. The 6–9% CAGR target assumes sustained pricing, continued synergy flow, and emerging-markets growth above 10% — the latter was 9% in 2025 (vs 12% in 2024) and ran at just 1% in Q4. Net debt at 1.9x EBITDA is manageable but is financed in part by a bridge loan to be refinanced in 2026 into a rising-rate environment.

What the reader should believe. The operating team has shown it can execute a hard integration and deliver near-term numbers. The portfolio is genuinely differentiated, biosolutions demand is structurally supported, and the innovation pipeline (HMOs, precision proteins, AI-led R&D, next-gen phytase) has real substance rather than slideware.

What the reader should discount. The framing of PPA-related earnings compression as a purely optical issue; the way pre-merger long-term targets were retired without an explicit reconciliation; "exit from certain countries" as a persistent but unquantified drag treated like a one-off; and the strong adjusted EBITDA margin narrative, which is genuine but is also doing more work than the equivalent EBIT margin narrative did pre-merger.

What's Next

Three dated prints and one live regulatory case stand between today's DKK 382 tape and the thesis resolution. The single watch-item is the Q1 2026 interim on May 5 — Bull and Bear both argue on whether the Q4 2025 0% in Agriculture/Energy/Tech was timing or structural, and the next print is the first clean read.

The Q4 2025 print (4% organic vs. 5.2% consensus, with Ag/Energy/Tech at 0%) broke a clean streak and triggered DKK 68–40 target cuts from Berenberg/JPMorgan. Management said the weakness is timing and reverses in 1H26. The next two prints — May 5 and August 20 — answer whether that call was right.

For / Against / My View

For

Disconfirming signal: Two consecutive quarters of sub-4% organic growth in 2026, OR a cut to the 37–38% FY26 adjusted EBITDA margin guide.

Against

Covering trigger: Organic growth re-accelerating to ≥7% in Planetary Health Biosolutions for two consecutive quarters with Ag/Energy/Tech back above 5%, alongside a FY26 EBITDA margin print of ≥37.5%.

The Tensions

1. The Q4 2025 Ag/Energy/Tech zero: timing or structural?

Bull says the 0% organic print in Agriculture/Energy/Tech was a customer inventory build-down that reverses in 1H26, exactly as management framed it — the segment grew 6% for the full year, and the Feed Enzyme Alliance contribution in the quarter was "offset by currency headwinds." Bear says the same zero is the first clear signal that underlying volume in 36% of sales is running below the 2030 GROW promise, with the "exit from certain countries" footnote already contributing a persistent 1–2pp organic headwind. Both cite the same data point — Q4 2025 Ag/Energy/Tech at 0% organic growth. This resolves on the May 5, 2026 Q1 interim and the August 20, 2026 H1 print: if Ag/Energy/Tech clears 4% in both, the timing read holds; if either prints below 5%, Bear's primary trigger is live.

2. ROIC at 5.6%: accounting artifact or capital-allocation verdict?

Bull says the 5.6% reported ROIC is a measurement artifact of the Chr. Hansen PPA and merger goodwill — the underlying business earns 10.1% ex-goodwill today and mid-teens by 2030, while cumulative 5-year operating cash flow is 175% of reported net income. Bear says the same 5.6% is the real economic return on capital deployed: EUR 13.5bn of enterprise value (Chr. Hansen + Feed Enzyme Alliance) is earning sub-6% blended, and management retired the "ROIC ≥ 20% including goodwill" target and restated 2030 ROIC excluding goodwill rather than hit the original measure. Both cite the same 5.6% adjusted ROIC including goodwill and the 16% ex-goodwill 2030 target. This resolves on observable ex-goodwill ROIC progression across the FY2026 and FY2027 prints — the 10.1% has to climb, not plateau, or the Bear read becomes the consensus read.

3. The synergy leg: over-delivery that extends to revenue, or over-delivery that stops at costs?

Bull says cost synergies hitting 100% run-rate a year early is evidence the playbook is working and the EUR 200M revenue-synergy leg by 2028 is under-priced — management has met or beaten every post-merger initial FY outlook. Bear says cost synergies are done; the 37–38% FY26 margin guide already assumes they are done, so from here the margin step has to come from operating leverage and revenue synergies on a P&L where Q4 2025 was the first consensus miss, three long-term targets have been retired, and the FY2026 guide sits at the low end of the just-launched 2030 range. Both cite the same 100%-early cost synergy delivery and the 6–9% 2030 GROW range. This resolves on the 2026 margin print relative to the 37–38% guide and the 2028 revenue-synergy disclosure: a 37.5%+ print in FY26 with documented revenue-synergy progress tips the Bull; any guide cut at the Q2 print or a 37% floor tips the Bear.

My View

Close call, slight edge to caution. The three tensions all resolve on two dated prints — Q1 on May 5, H1 on August 20 — and the asymmetry sits against the buyer at 33× forward: a single sub-5% Ag/Energy/Tech print compresses the multiple before the 12–18 month Bull setup has time to work, while a clean 7%+ print mostly re-rates the stock back toward consensus DKK 455 — where Bull and consensus already sit. The tension that tips my scale is the first one, because every other argument in this file is a translation of whether Q4 2025 was timing or structural. I'd wait for the Q1 2026 print rather than underwrite the timing-reversal call on management's say-so — the first post-merger consensus miss deserves one confirming data point. The one condition that would flip me positive: Q1 2026 Ag/Energy/Tech prints above 4% with group organic at 5%+ and the 37–38% FY26 margin guide reaffirmed — at that point the Q4 zero was timing, the synergy playbook is intact, and the 25.7× ex-PPA multiple is the right frame, not the 41× IFRS one.

Web Research — What the Internet Knows

Bottom line from the web. The single most important thing the internet reveals that the filings alone don't is the sell-side's sharp re-pricing of Novonesis after the Q4 2025 miss on Feb 25, 2026 — organic growth came in at 4% vs. 5.2% consensus, Planetary Health Agriculture-Energy-Tech was flat in euros, and adjusted EBITDA of EUR 364.6M was EUR 10M light. Inside a month, Danske Bank, BNP Paribas, UBS, Berenberg, SEB, Nordea, Jyske Bank all trimmed targets — but the consensus still sits at DKK 458-466 vs. a DKK 381 spot, an 18-22% upside call that reflects continued faith in the 2030 "GROW" strategy (6-9% CAGR, ~39% EBITDA margin, 16% ROIC ex-goodwill) even as near-term estimates get cut. Separately, the Turkish Competition Board fined Novonesis in March 2025 as part of an active abuse-of-dominance investigation into industrial enzymes — a live regulatory risk the specialists would not have caught from the European filings alone.

1. What Matters Most

Q4 2025 miss triggered a broad target-price reset — but analysts still see 18-22% upside

Novonesis reported weaker-than-expected Q4 2025 on Feb 25, 2026: organic growth of 4% vs. 5.2% consensus, with Planetary Health's Agriculture, Energy & Tech unit flat in euros. Quarterly adjusted EBITDA of EUR 364.6M (USD 429.9M) missed by ~EUR 10M. 2026 guidance: 5-7% organic growth and 37-38% adj EBITDA margin, including ~50bps of FX headwinds. The share price fell on the print and has drifted to DKK 381.85 (Apr 22, 2026), down 6.28% YTD. Source: Reuters, Feb 25, 2026.

Turkish Competition Authority is actively investigating abuse of dominance in industrial enzymes

On March 27, 2025, the Turkish Competition Board (TCA) imposed an administrative fine on Novonesis A/S and subsidiaries for providing "incomplete, incorrect, or misleading" responses to information requests during an Article 6 investigation into alleged abuse of dominant position in the industrial enzymes market. The Board fined Novonesis 0.1% of annual gross revenues under Art. 16(1)(c) TCA plus a daily fine of 0.15% for each day of non-compliance regarding missing fungal alpha-amylase customer contracts. The underlying dominance case is still open. Source: LBF Partners, Sep 2025.

EUR 1.5bn Feed Enzyme Alliance buy-in closed June 2, 2025 — the first real bolt-on test

Novonesis closed the acquisition of dsm-firmenich's share of the Feed Enzyme Alliance for EUR 1.5bn (USD 1.6bn) on June 2, 2025, taking over sales and distribution of a business that generated roughly EUR 300M revenue in its last year as a JV. The deal was announced Feb 11, 2025 and is fully folded into Planetary Health. NIBD/EBITDA moved to 2.1x post-close, within the ~1.5x long-run target. Reuters notes the acquisition's revenue contribution to Q4 AgEnergyTech was "offset by currency headwinds," which is why the reported segment looked flat. Source: Reuters, Feb 11, 2025; FeedBusiness MEA, Jun 4, 2025.

2030 "GROW" strategy quietly retires pre-merger ambition, but management accepts lower ROIC bar

At the Aug 20, 2025 Capital Markets event, CEO Ester Baiget announced 2030 targets: 6-9% organic CAGR, ~39% adj EBITDA margin, ~16% adj ROIC ex-goodwill (up from pro-forma 8.3% in 2024). Capital allocation: 40-60% of adj net profit returned as dividends; target NIBD/EBITDA of ~1.5x; capex elevated near-term for ERP rollout and sustainability investments, trending down to high-single-digit % of sales. Historian's specialist question — did sell-side notice the silent retirement of the pre-merger "double sales by 2030" and the ROIC-incl-goodwill target? — the web answer is: no pushback. Analyst reaction was positive; one commentator called it "ambitious but achievable." Source: Novonesis, Aug 20, 2025.

Novo Holdings controls 25.5% of share capital, 70.1% of votes — and the Chair just took Novo Nordisk

Novo Holdings A/S (a subsidiary of the Novo Nordisk Foundation) owns the Class A shares plus ~5.8M B shares, totaling 25.5% economic / 70.1% voting control. On Nov 14, 2025, the Novo Nordisk Foundation completed a takeover of the Novo Nordisk (pharma) board, installing former CEO Lars Rebien Sørensen as Chair — and appointing Cees de Jong, who is currently Chair of Novonesis, as Vice Chair of Novo Nordisk. Source: BioSpace, Nov 14, 2025; Novonesis governance page.

Insider selling: CSO Claus Crone Fuglsang sold DKK 2.3M in shares on March 26, 2026

EVP & Chief Science Officer Claus Crone Fuglsang reported selling DKK 2.3M (USD ~320K) worth of Novonesis B shares on March 26, 2026, one month after the Q4 miss and while analysts were actively cutting price targets. This is the first material flagged insider sale post-Q4 results — small in size relative to total comp but notable for timing. Source: MarketScreener, Mar 26, 2026.

EUR 100M buyback completed June 27, 2025; dividend yield ~1.7%

The EUR 100M (DKK 746M) buyback was launched in March 2025 and completed on schedule June 27. Novonesis trades at 32.8x 2026E P/E with a 1.7% 2026E dividend yield and 2.81% FCF yield — capital return is growing but still modest relative to the growth-investment phase. An interim dividend of DKK 2.25 per share (EUR 0.30) was approved for H1 2025. Source: Novonesis H1 2025 release; MarketScreener.

New Thai production plant acquired April 17, 2026 for USD 50M — Southeast Asia expansion tangible

Novonesis agreed to acquire a manufacturing plant in Rayong, Thailand from MeiHua Holdings for approximately USD 50M, intended as a fermentation hub to support Southeast Asia demand including HMO (human milk oligosaccharides). Full commercial operation targeted by 2027. Together with recent investments in North Carolina, China, Brazil, and Wisconsin, this is the physical build-out of the capex-heavy 2030 GROW strategy. Source: IndexBox, Apr 17, 2026; Saxo/CI, Apr 8, 2026.

EUR 4bn EMTN bond programme listed in March 2026 — S&P rating A- (stable)

On March 10, 2026, Novonesis established a EUR 4bn Euro Medium Term Note programme on the Luxembourg Stock Exchange and issued three bonds totaling EUR 1.7bn: EUR 500M 3.25% 2030, EUR 600M 3.625% 2033, EUR 600M 4.00% 2037. S&P Global Ratings assigns a corporate rating of A- stable. This is a solid investment-grade profile that reflects the merger-related leverage absorption. Source: Novonesis Debt Investors page.

Jacob Vishof Paulsen — EVP Food & Beverage — departed March 31, 2025

Paulsen, a 19-year Chr. Hansen veteran and member of the Executive Leadership Team, left for a role outside Novonesis. Food & Beverage Biosolutions is the legacy Chr. Hansen stronghold, and his departure so early in the integration is a watch item. Source: Novonesis, Feb 21, 2025.

2. Recent News Timeline

3. What the Specialists Asked

4. Insider Spotlight

Novo Holdings A/S — 25.5% capital / 70.1% votes

Through Class A shares plus 5.8M B shares, Novo Holdings (the investment arm of the Novo Nordisk Foundation) holds voting control. The Foundation's simultaneous takeover of Novo Nordisk's board in November 2025, installing former Novo Nordisk CEO Lars Rebien Sørensen as Chair and Novonesis Chair Cees de Jong as Vice Chair of Novo Nordisk, tightens the governance interlock across the Novo Group. No material stake changes disclosed in the pool since the merger close.

Ester Baiget — President & CEO (since 2020)

25 years at Dow before Novonesis; led Novozymes through the Chr. Hansen merger close (Jan 2024) and the 2030 GROW strategy launch (Aug 2025). External commentary (IMD, Harding Loevner) consistently positive on operational execution. Personal share ownership not disclosed in the search pool. No insider sales attributed to her in the last 12 months.

Claus Crone Fuglsang — EVP & Chief Science Officer

Sold DKK 2.3M (USD ~320K) of B-shares on March 26, 2026, ~one month after the Q4 miss and amid active target-price revisions. Small in absolute terms but notable for timing.

Jacob Vishof Paulsen — former EVP Food & Beverage Biosolutions

Left effective March 31, 2025 for a role outside Novonesis after 19 years in the Chr. Hansen lineage. Legacy Chr. Hansen leadership retention in a critical integration year is a watch item.

5. Industry Context

Specialty chemicals: 4-6% long-run CAGR, but 2026 US production expected essentially flat

Consensus forecasts for specialty chemicals point to 4.3-6.3% CAGR through 2030. However, Deloitte's 2026 outlook notes deal-making is at post-COVID lows (243 deals in H1 2025), and the American Chemistry Council flags US chemical production is expected to be "essentially flat (off by 0.2%)" in 2026. Oliver Wyman sees global production at 3.5%, with energy-intensive European operators (Novonesis Danish/Spanish plants) still absorbing structural cost disadvantage. Source: Deloitte; American Chemistry Council; Oliver Wyman 2026.

Biosolutions-specific demand set: decarbonization + emerging-markets tailwind

Novonesis' end-markets sit squarely in biosolutions pull-through: 83% of 2024 sales aligned with UN Sustainability Development Goals; R&D at ~20% of sales vs. industry norm of 10-15%; emerging markets grew 12% in H1 2025 vs. 8% in developed markets. The reference frame is Givaudan-like economics, not diversified specialty chemicals. Source: AInvest.

Competitive positioning — effective duopoly in cultures, near-monopoly in dairy

Post-merger Novonesis holds ~50% share in industrial enzymes and ~70% in dairy cultures globally. The second-largest enzyme player (IFF/DuPont N&B) is operationally challenged, and the Chinese generic enzyme tier (Vland, Sunson, Longda) competes in the commodity end, not specialty. Morningstar notes Novonesis' core markets "offer relatively low growth prospects, which means the company is now relying more on new markets and inorganic growth initiatives" — a caveat to the quality framing. Source: PitchBook; Morningstar.